- Represented Aurigene Discovery Technologies Limited in its exclusive global license agreement with Olema Pharmaceuticals, Inc. for novel small molecule inhibitors of an undisclosed oncology target (June 2022).
- Represented Neuropore Therapies, Inc. in its license agreement with Global Cancer Technology for a portfolio of Neuropore's small molecule autophagy modulators for the treatment of cancers and other diseases, excluding neurodegenerative disorders (September 2020).
- Represented REMD Biotherapeutics Inc. in its license agreement with GenScript ProBio for GenScript's bispecific antibody derived from its single-domain antibody fused to monoclonal antibody (SMAB) platform (September 2020).
- Represented Revolution Medicines, Inc. in its license agreement with Ginkgo Bioworks for Revolution Medicine's WDB002 compound to treat infectious disease, including COVID-19 (June 2020).
- Represented Allele Biotechnology and Pharmaceuticals, Inc. in its license agreement with Astellas Institute for Regenerative Medicine to expand Astellas' access to Allele’s induced pluripotent stem cell (iPSC) technologies for various cell therapy programs (January 2020).
- Represented Revolution Medicines, Inc. in its collaboration agreement with Amgen Inc. for Amgen to conduct a Phase 1B clinical study of the combination of Revolution Medicines' investigational SHP2 inhibitor and Amgen's investigational KRASG12C inhibitor (November 2019).
- Represented Aeromics, Inc. in its collaboration and license agreement with Simcere Pharmaceutical Group for Greater China rights to AER-271, an anti-edema therapy, being developed for the treatment of stroke and other indications (November 2019).
- Represented Aurigene Discovery Technologies Limited in its collaboration, option and license agreement with Exelixis, Inc. for up to six Aurigene programs (July 2019).
- Represented AliveGen Inc. in its sale of muscle-enhancing drug candidates targeting myostatin, ALG-801 and ALG-802, to Biogen for an upfront payment of $27.5 million and additional potential milestone payments of $535 million (July 2018).
- Represented Onconova Therapeutics, Inc. in its license agreement with Pint Pharma GmbH to commercialize anti-cancer compound, rigosertib, in Latin America in exchange for an equity investment, potential milestone payments of $42.75 million and double-digit royalties (March 2018).
- Represented Onconova Therapeutics, Inc. in its license and collaborative development agreement with HanX Biopharmaceuticals, Inc. for development and commercialization of Onconova's CDK4/6 and ARK5 dual inhibitor, ON 123300, in China (December 2017).
- Represented California Safe Soil, LLC in its $3.0 million equity financing transaction (August 2017).
- Represented Novogene Co. Ltd. in its agreement with Trovagene, Inc. for the purchase of NextCollect™, Trovagene's proprietary urine collection and nucleic acid preservation device, for validation in the Chinese market (July 2017).
- Represented Arrien Pharmaceuticals, LLC in its worldwide license agreement with a U.S.-based pharmaceutical company for Arrien's Phase 1 clinical agent, ARN-6039, and Arrien’s series of ROR-γt targeting compounds (June 2017).
- Represented Debiopharm International SA in its acquisition of ImmunoGen, Inc.'s CD37 antibody-drug conjugate product, IMGN529 (May 2017).
- Represented Aurigene Discovery Technologies Limited in its license agreement with Agios Pharmaceuticals, Inc. for Aurigene's portfolio of small molecule inhibitors of an undisclosed cancer metabolism target (April 2017).
- Represented Allele Biotechnology and Pharmaceuticals, Inc. in its $11.0 million equity financing transaction (October 2016).
- Represented Aurigene Discovery Technologies Limited in an amendment to its collaboration, license and option agreement with Curis, Inc. to receive 10.2 million shares of Curis common stock in lieu of up to $24.5 million of milestone and other payments (September 2016).
- Represented California Safe Soil, LLC in its $2.75 million equity financing transaction (December 2015).
- Represented DNAtrix, Inc. in its immuno-oncology Phase 2 clinical study collaboration with Merck to evaluate DNX-2401 in combination with KEYTRUDA® (pembrolizumab) (October 2015).
- Represented GRI Bio, Inc. in its $4.4 million equity financing transaction (April 2015).
- Represented Allele Biotechnology and Pharmaceuticals, Inc. in its license agreement with Ocata Therapeutics, Inc. for Allele's proprietary technology for generating human induced pluripotent stem cells (iPSCs). (March 2015).
- Represented Aurigene Discovery Technologies Limited in its collaboration, license and option agreement with Curis, Inc. for immuno-oncology and selected precision oncology targets (January 2015).
- Represented California Safe Soil, LLC in its $2.7 million convertible note financing transaction (December 2014).
- Represented Allele Biotechnology and Pharmaceuticals, Inc. in its $7.0 million equity financing transaction (August 2014).
- Represented Aurigene Discovery Technologies Limited in its collaborative license, development and commercialization agreement with Pierre Fabre Pharmaceuticals for worldwide rights (excluding India) to AUNP12, an immune checkpoint modulator targeting the PD-1 pathway (February 2014).
- Represented Quest Diagnostics in the sale to Royalty Pharma of royalty rights from commercialization of the drug candidate ibrutinib for $485 million (July 2013).
- Represented Micro-Imaging Solutions in its license agreement with Fujikura Ltd to jointly co-market nano-sized, complementary metal-oxide semiconductor, or CMOS, based endoscopes (May 2013).
- Represented NovaBay Pharmaceuticals, Inc. in its collaboration and license agreement with Virbac for exclusive worldwide rights to NovaBay's proprietary compound, auriclosene (NVC-422), for global veterinary markets (May 2013).
- Represented Kindstar Diagnostics Co. Ltd. in agreements to obtain rights to various diagnostic tests and technology in China, including agreements with Illumina, Mayo Medical Laboratories, BG Medicine, Pathwork Diagnostics, TessArae, BioView and Singulex (June 2011-May 2013).
- Represented Soligenix, Inc. in its collaboration with Intrexon to develop and commercialize human monoclonal antibody therapies for new biodefense and infectious disease applications for Melioidosis (May 2013).
- Represented Apricus Biosciences, Inc. in its sale of Totect (dexrazoxane HCl), a marketed injectable treatment for anthracycline extravasation, to Biocodex USA (April 2013).
- Represented Intelligent Medical Devices, Inc. (IMDx) in connection with its development and license agreement with Qiagen to design, develop and manufacture several undisclosed CE-marked and FDA cleared diagnostic tests for use on Qiagen's flagship QIAsymphony RGQ automated platform (January 2013).
- Represented Apricus Biosciences, Inc. in connection with its co-promotion agreement, asset-purchase agreement and assignment agreement with PediatRx relating to the pharmaceutical products Granisol® and Aquoral™ (February 2012).
- Represented Santarus, Inc. in connection with its commercialization agreement with Depomed, Inc. to expand Santarus' commercial, manufacturing and regulatory responsibilities for GLUMETZA (August 2011).
- Represented Intelligent Medical Devices, Inc. (IMDx) in connection with its agreement with Abbott Laboratories for the design, development and manufacture by IMDx of molecular diagnostic tests to be distributed by Abbott worldwide (January 2011).
- Represented NexMed (U.S.A.), Inc., a wholly owned subsidiary of Apricus Biosciences, Inc., in connection with its license agreement with Ellis Pharmaceuticals for the commercialization of NexMed's Vitaros product in the Gulf countries and part of the Middle East (January 2011).
- Represented NexMed (U.S.A.), Inc., a wholly owned subsidiary of Apricus Biosciences, Inc., in connection with its license agreement with Bracco SpA for the commercialization of NexMed's Vitaros product in Italy (December 2010).